StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

(R)-(4-Oxido-10-oxo-7-palmitoyl-3,5,9-trioxa-4-phosphapentacosyl)trimethylammonium-4-oxid

Colfosceril Palmitate

HCID 452110
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
63-89-8
Standard-SMILES
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
InChIKey
KILNVBDSWZSGLL-KXQOOQHDSA-N
Summenformel
C40H80NO8P
Durchschnittliche Molmasse
734 g/mol
Monoisotopische Masse
733,56215551

Überblick

1,2-dihexadecanoyl-sn-glycero-3-phosphocholine is a phosphatidylcholine 32:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl). A synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of pulmonary surfactants. It has a role as a surfactant and a mouse metabolite. It is a phosphatidylcholine 32:0 and a 1-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine. It is functionally related to a hexadecanoic acid. It is a conjugate base of a 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine.

Namen und Bezeichner

Bevorzugter Name
Colfosceril Palmitate
IUPAC
[(2R)-2,3-di(hexadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
Lokaler Name
(R)-(4-Oxido-10-oxo-7-palmitoyl-3,5,9-trioxa-4-phosphapentacosyl)trimethylammonium-4-oxid
Englischer Name
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine
Summenformel
C40H80NO8P
Molmasse
734.04

Namen und Synonyme

63-89-8Colfosceril palmitate1,2-Dipalmitoyl-sn-glycero-3-phosphocholinediPalmitoylphosphatidylcholinePalmitate de colfoscerilPalmitato de colfosceriloColfoscerili palmitas1,2-dihexadecanoyl-sn-glycero-3-phosphocholineColfoscerilDppc, l-Dppc, r-Dipalmitoyl lecithin, l-
Weitere Namen anzeigen
DPPC1,2-dipalmitoyl-sn-glycero-3-PC16:0 PCDIPALMITOYL LECITHINL-A-LECITHIN DIPALMITOYLDIPALMITOYL-L-ALPHA-LECITHINB,G-DIPALMITOYL-L-A-LECITHINL-ALPHA-LECITHIN, DIPALMITOYL
DTXSID5046720129Y83319X2NFW0ADipalmitoyl glycerophosphocholine1-16:0-2-16:0-phosphatidylcholine[(2R)-2,3-di(hexadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphateSURFAXIN COMPONENT DPPCDTXCID3026720

Datenbank-Bezeichner

Eigenschaften

Berechnete Struktureigenschaften

XLogP
13,5
Polarare Oberfläche (TPSA)
111 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
40
Schwere Atome
50
Formalladung
0
Komplexität
826

Experimentelle und physikochemische Eigenschaften

Lipids · 2 Einträge

Lipids -> Unambiguous Lipids

Lipids -> Glycerophospholipids [GP] -> Glycerophosphocholines [GP01] -> Diacylglycerophosphocholines [GP0101]

SolubilityVery poor solubility
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Boiling Point60.5-61.5ºC at 760 mmHg
Melting Point-63ºC
Physical DescriptionSolid
Collision Cross Section · 2 Einträge

283.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Sample Type: Human plasma; Dataset: Unambiguous Lipids]

281.91 Ų [M+H]+ [CCS Type: TIMS; Method: single field calibrated]

Physikochemische Eigenschaften

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS ClassificationNot Classified

Gefahrenhinweise

Regulatory InformationColfosceril palmitate: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesNot Classified

Sicherheitsdaten

F
10-21
wgk
3
hs_code
29232000
safety_code
24/25
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

R - Respiratory system

QR - Respiratory system

Protein BindingColfosceril palmitate stays and gets metabolized in the pulmunar tissue, thus it is not able to bind to plasma proteins.
Pharmacodynamics · 1 Eintrag

Colfosceril palmitate has shown to significantly reduce the risk of pneumothoraces, pulmonary interstitial emphysema and mortality. Unlike naturals surfactants, colfosceril palmitate reduces the risk of bronchopulmonary dysplasia, intraventricular hemorrhage and patent ductus arteriosus. In clinical placebo-controlled trials, there was a significant reduction in the number of deaths attributed to hyaline membrane disease, the incidence of pulmonary air leaks, oxygen requirements and mean airway pressure. Some reports have indicated a lack of therapeutic effect due to the absence of surfactant protein.

Mechanism of Action · 1 Eintrag

Treatment with colfosceril palmitate aims to reinflate a collapsed area of the lung, improve compliance and reduce intrapulmonary shunting. The actions of colfosceril palmitate are perfomed by replacing the defficient or innefective endogenous lung surfactant and thus, reducing the tension and stabilizing the alveoli from collapsing. Colfosceril palmitate will form a very thin film that will cover the surface of the alveolar cells and therefore it will reduce surface tension.

Biological Half-LifeThe half-life of colfosceril palmitate is registered to be in the range of 20-36 hours.
Metabolism/MetabolitesColfosceril palmitate is catabolized and reutilized for further synthesis and secretion in lung tissues.
Absorption, Distribution and Excretion · 4 Einträge

The absorption is done directly in the alveolus into the lung tissue. As the lung surfactant is distributed in the bronchi, bronchioles and alveoli, its highest concentration is at the alveolar air-fluid interface where it remains as a monolayer.

Zugehörige Reaktionen

13
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 37756
HRID 37756als Edukt
Reaktionsgleichung von HRID 230978
HRID 230978als Edukt
Reaktionsgleichung von HRID 230979
HRID 230979als Edukt
Reaktionsgleichung von HRID 230980
HRID 230980als Edukt
Reaktionsgleichung von HRID 399366
HRID 399366als Edukt
Reaktionsgleichung von HRID 481280
HRID 481280als Edukt
Reaktionsgleichung von HRID 1825693
HRID 1825693als Edukt
Reaktionsgleichung von HRID 1865764
HRID 1865764als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CAS
63-89-8
PubChem CID
452110
DTXSID
DTXSID5046720
ChEMBL
CHEMBL1200737
ChEBI
CHEBI:72999
UNII
319X2NFW0A
EC Number
200-567-6
Nikkaji
J110.766F
Schmelzpunkt
229 · 229-229.5 °C
storage temp.
-20 °C · -20°C
Löslichkeit
Chloroform (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
Farbe
White to Off-White
Biologische Quelle
synthetic
Merck
14 · 14,2477
Stabilität
Stable. Incompatible with strong oxidizing agents.
Kosmetik-Inhaltsstoffe Funktionen
SKIN CONDITIONING
InChIKey
KILNVBDSWZSGLL-KXQOOQHDSA-N
SMILES
[C@@H](OC(=O)CCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)COP([O-])(=O)OCC[N+](C)(C)C |&1:0,r|
CAS Datenbank
63 · 63-89-8(CAS DataBase Reference)

After 5 days, most of the administered dose (56%) is distributed throughout the body with renal and fecal excretion being the minor elimination pathway representing the 4 and 2% of the eliminated dose respectively. The major route of elimination is by expelled air which accounts for 28% of the administered dose.

Colfosceril palmitate is distributed uniformly to all lobes of the lung, distal airways and alveolar spaces. It will not enter the systemic circulation in healthy lungs, however when the integrity of the tissue is distrupted colfosceril can reach systemic circulation. Even 5 days after administration, there are traces of colfosceril palmitate retained in the body that represented 72% of the administered dose which by then have entered pathways of lipid metabolism to become tissue associated.

After 5 days of drug administration, the lung and liver would contain 10% of the administered dose and the elimination via renal excretion accounts only for 8% of the administered dose. This proved a very small renal clearance and confirmed that the major elimination route is by expired air.

Tissue LocationsPlacenta
Cellular LocationsCytoplasm
Metabolite PathwaysPhosphatidylcholine Biosynthesis PC(16:0/16:0)
Anwendungen · 1 Eintrag

Verwenden1,2-dipalmitoyl-sn-glycero-3-phosphocholine is a major phospholipid constituent and primary surface tension lowering component of natural lung surfactant. Colfosceril Palmitate is used as pulmonary surfactant and diagnostic aid (fetal lung maturity).

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

TYLOXAPOLHexadecanoic acid, 1,1'-[1-[[(2-oxido-1,3,2-dioxaphospholan-2-yl)oxy]methyl]-1,2-ethanediyl] ester[S,(+)]-1-O,2-O-Dipalmitoyl-3-O-trityl-L-glycerol2-Chloroethylphosphoric acid dichlorideCholinglycerophosphat(S)-1-(Hydroxymethyl)ethan-1,2-diyldipalmitatCholine tosylatePalmitinsure15%)">Trimethylamin, in wässriger Lösung(C > 15%)

Nachgelagerte Produkte

1,2-Dipalmitoyl-sn-glycero-3-phosphobutanol (sodium salt)
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A phosphatidylcholine 32:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl). A synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of pulmonary surfactants.